Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant CCR4 (Mogamulizumab Biosimilar) antibody

Reactivity: Human Dep Host: Rabbit Chimeric KW-0761 unconjugated Recombinant Antibody
Catalog No. ABIN7072382
  • Target See all CCR4 (Mogamulizumab Biosimilar) products
    CCR4 (Mogamulizumab Biosimilar)
    Antibody Type
    Recombinant Antibody
    Reactivity
    Human
    Host
    • 1
    • 1
    Rabbit
    Clonality
    • 1
    • 1
    Chimeric
    Conjugate
    • 2
    This CCR4 (Mogamulizumab Biosimilar) antibody is un-conjugated
    Application
    • 1
    • 1
    Depletion (Dep)
    Purpose
    Anti-CCR4 [KW-0761 (Mogamulizumab)], Rabbit IgG, kappa
    Specificity
    This antibody is specific for human CCR4, a chemokine receptor that is preferentially expressed by Th2 and regulatory T (Treg) cells. CCR4 is also detected on basophils, platelets, monocytes and brain microvascular and coronary artery endothelial cells.
    Characteristics

    Original Species of Ab: Human

    Original Format of Ab: IgG1

    Purification
    Protein A affinity purified
    Immunogen
    This antibody was prepared by humanization of a mouse anti-CCR4 mAb.
    Clone
    KW-0761
    Isotype
    IgG kappa
  • Application Notes
    The clinically used format of this antibody (which underwent additional de-fucosylation to increase antibody-dependent cellular cytotoxicity (ADCC)), has significant clinical activity in heavily pretreated patients with mycosis fungoides and Sézary syndrome, and is associated with an overall response rate of 36.8 % and a median duration of response of 10.4 months (Duvic et al, 2014). It was shown to CCR4-expressing cells by antibody-dependent, cell-mediated cytotoxicity (ADCC). Therapeutically, this results in a dual mechanism of action, in addition to directly targeting malignant T cells over-expressing CCR4, this antibody also depletes T reg cells, an important therapeutic target in human cancers. This antibody is well-tolerated, and administration does not appear to trigger clinically significant autoimmune complications in phase 1/2 trials (Duvic et al, 2014). This antibody has been approved in Japan for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma, and is in clinical trials for solid cancers. For the avoidance of doubt - the material produced by Absolute Antibody has not been de-fucosylated.
    Comment

    This chimeric rabbit antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.

    Restrictions
    For Research Use only
  • Concentration
    1 mg/mL
    Buffer
    PBS with 0.02 % Proclin 300.
    Preservative
    ProClin
    Precaution of Use
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    4 °C,-20 °C
    Storage Comment
    Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.
  • Target
    CCR4 (Mogamulizumab Biosimilar)
    Abstract
    CCR4 (Mogamulizumab Biosimilar) Products
    Target Type
    Biosimilar
    Background
    CD194, CKR-4, CCR-4, CCR4, K5-5
    UniProt
    P51679
You are here:
Support